引用文本：蓝志煌, 陈国骥, 魏巍, 等. 基于Web of Science核心数据库对2015—2024年结直肠癌奥沙利铂耐药研究的可视化分析[J/CD]. 消化肿瘤杂志（电子版）, 2026, 18(1): 108-116.

作者：蓝志煌¹，陈国骥²，魏巍¹，杨舒婷¹，张楠²，张清^1,2

单位：1. 广东医科大学第一临床医学院，广东 湛江 524000；2. 肇庆市第一人民医院胃肠肛肠外科，广东 肇庆 526000

Authors：Lan Zhihuang¹, Chen Guoji², Wei Wei¹, Yang Shuting¹, Zhang Nan², Zhang Qing^1,2

Unit：1. First School of Clinical Medicine, Guangdong Medical University, Zhanjiang 524000, Guangdong, China；2. Department of Gastrointestinal and Anorectal Surgery, the First People's Hospital of Zhaoqing, Zhaoqing 526000, Guangdong, China

摘要：

目的 探讨结直肠癌奥沙利铂耐药研究领域的研究力量分布及研究热点与趋势，为未来开展结直肠癌奥沙利铂耐药研究提供参考。方法 检索Web of Science核心数据库中2015年1月至2024年12月发表的结直肠癌奥沙利铂耐药研究相关文献，应用CiteSpace软件对该研究领域的作者、国家、关键词进行可视化分析。通过共现分析、聚类分析和关键词突现分析，揭示该领域的研究现状、热点演变及未来趋势。结果 共纳入1096篇文献（均为论著）。2015—2024年结直肠癌奥沙利铂耐药研究相关文献的年度发文量整体呈上升趋势。该研究领域的研究力量中，最活跃的作者是Ba Y和Zhang HY，发文总篇数均为7篇，作者合作主要发生于团队内部，团队间合作较少。中国（573篇）、美国（133篇）、日本（78篇）为发文量排名前3位的国家。中国的中介中心性为0.19，仅次于美国（0.39）。出现频次排名前 3 位的关键词依次为表达（279次）、细胞（151次）、转移性结直肠癌（149次），转移性结直肠癌细胞的异常表达及联合用药的探索是该领域的研究重点。突现分析显示，促耐药机制（突现强度3.56，2021—2024年）、通路阻断（突现强度3.62，2022年）、迁移侵袭（突现强度3.82，2023—2024年）、具核梭形杆菌（突现强度3.82，2023—2024年）在近期出现频率激增，为该领域研究的最新趋势。结论 结直肠癌奥沙利铂耐药研究持续受到学界关注，中国为该领域的研究做出重大贡献，通过加强国际合作，可以提升其在该领域研究中的国际影响力。在结直肠癌奥沙利铂耐药研究中，耐药机制与联合用药是研究的重点，未来的研究方向集中于通路阻断方式、肿瘤迁移侵袭机制及肠道菌群与肿瘤微环境相互作用的探索。

关键词：结直肠癌；奥沙利铂；化疗耐药；CiteSpace；可视化分析

Abstract：

Objective To explore the distribution of research forces, research hotspots and trends in the field of oxaliplatin resistance research in colorectal cancer, and to provide a reference for future studies in this field. Method Literature related to oxaliplatin resistance in colorectal cancer published from January 2015 to December 2024 was retrieved from the Web of Science Core Collection database. CiteSpace was applied to perform a visual analysis of authors, countries, and keywords in this research field. Co-occurrence analysis, clustering analysis, and keyword burst detection were used to reveal the current research landscape, the evolution of hotspots, and future trends in this field. Result A total of 1096 articles (all original research papers) were included. From 2015 to 2024, the annual publication volume of studies on oxaliplatin resistance in colorectal cancer showed an overall upward trend. Among the research forces in this field, the most active authors were Ba Y and Zhang HY, each with 7 publications. Author collaboration primarily occurred within their respective teams, while inter-team collaboration remained limited. China (573 articles), the United States (133 articles), and Japan (78 articles) ranked as the top three countries in publication volume. China had a betweenness centrality of 0.19, second only to the United States (0.39). The most frequent keywords were expression (279 occurrences), cell (151 occurrences), and metastatic colorectal cancer (149 occurrences). Studies on abnormal expression in metastatic colorectal cancer cells and the exploration of combination therapy were major research topics in this field. Burst detection revealed that drug resistance-promoting mechanism (burst intensity 3.56, 2021-2024), pathway blockade (burst intensity 3.62, 2022), migration and invasion (burst intensity 3.82, 2023-2024), and Fusobacterium nucleatum (burst intensity 3.82, 2023-2024) have shown a sharp increase in recent years, representing the latest research trends in this field. Conclusion Research on oxaliplatin resistance in colorectal cancer has continued to attract academic attention. China has made significant contributions to this field, and strengthening international cooperation can further enhance its global influence of research in this area. In studies on oxaliplatin resistance in colorectal cancer, the mechanisms of resistance and combination therapy are major research foci. Future research directions will center on exploring approaches to pathway blockade, as well as investigating tumor migration and invasion, and the interactions between the gut microbiota and the tumor microenvironment.

Key words：Colorectal cancer; Oxaliplatin; Chemoresistance; CiteSpace; Visualization analysis

注：网络优先发布